Gentium S.p.A. (NASDAQ: GENT), a biopharmaceutical company, specializes in discovering, researching, developing and manufacturing active ingredients derived from natural sources as potential therapeutic agents. The company focuses on developing relationships with industrial and academic institutions and intends to discover further beneficial effects of its products as well as develop pharmaceuticals with a broader range of treatment indications. For further information, visit the Company’s web site at http://www.gentium.com.
- 17 years ago
QualityStocks
Gentium S.p.A. (NASDAQ: GENT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Expands Sports.com Brand with NBA Yearbook Campaign Covering Seven Iconic Franchises
SEGG Media (NASDAQ: SEGG, LTRYW), parent company of Sports.com, announced a major step in its…
-
ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Completes Montauban Mill Building Construction; Transitions to Equipment Sourcing, Delivery, and Installation
This article has been disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and…
-
Strawberry Fields REIT Inc. (NYSE American: STRW) Announces Q3 2025 Financial Results, Holds Quarterly Earnings Call
Strawberry Fields REIT announced financial results for the quarter ending September 30th 2025, and also…